


**IN THE CLAIMS:**

Please cancel claims 13-16 without prejudice or disclaimer and amend the claims as shown below.

1-6. Previously cancelled

1-7. (Currently amended) A method of increasing sexual desire, interest or performance in a human in need of increased sexual desire, interest or performance, said method which comprises orally administering a sexually useful effective amount ranging from about 0.2 thru about 8 mg/person/dose of a compound of the formula (A)



where

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and are:

-H,  
C<sub>1</sub>-C<sub>6</sub> alkyl,  
C<sub>3</sub>-C<sub>5</sub> alkenyl,  
C<sub>3</sub>-C<sub>5</sub> alkynyl,  
C<sub>3</sub>-C<sub>5</sub> cycloalkyl,  
C<sub>4</sub>-C<sub>10</sub> cycloalkyl,  
phenyl substituted C<sub>1</sub>-C<sub>6</sub> alkyl,  
or -NR<sub>1</sub>R<sub>2</sub> is a pyrrolidyl, piperidinyl, morphoninyl, 4-methyl piperazinyl

or imidazolyl;

X is:

-H,

C<sub>1</sub>-C<sub>6</sub> alkyl,  
-F, -Cl, -Br, -I,  
-OH,  
C<sub>1</sub>-C<sub>6</sub> alkoxy,  
cyano,  
carboxamide,  
carboxyl,  
(C<sub>1</sub>-C<sub>6</sub> alkoxy)carbonyl,

A is:

CH,  
CH<sub>2</sub>,  
CH-(halogen) where halogen is -F, -Cl, -Br, -I,  
CHCH<sub>3</sub>,  
C=O,  
C=S  
C-SCH<sub>3</sub>,  
C=NH,  
C-NH<sub>2</sub>  
C-NHCH<sub>3</sub>,  
C-NHCOOCH<sub>3</sub>,  
C-NHCN,  
SO<sub>2</sub>,  
N;

B is:

CH<sub>2</sub>,  
CH,  
CH-(halogen) where halogen is as defined above,  
C=O,  
N,  
NH,  
N-CH<sub>3</sub>,

D is:

CH,  
CH<sub>2</sub>,  
CH-(halogen) where halogen is as defined above,  
C=O,  
O,  
N,  
NH,  
N-CH<sub>3</sub>;

and n is 0 or 1, and where ~~-----~~ is a single or double bond, with the provisos:

(1) that when n is 0, and

A is CH<sub>2</sub> CH-(halogen) where halogen is as defined above, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>;

then D is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-CH<sub>3</sub>;

(2) that when n is 0, and

A is CH, C-SCH<sub>3</sub>, C-NH<sub>2</sub>, C-NHCH<sub>3</sub>, C-NHCOOCH<sub>3</sub>, C-NHCN, N; then  
D is CH, N;

(3) that when n is 1, and

A is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>; and

B is CH<sub>2</sub>, CH-(halogen) where halogen is as defined above, C=O, NH, N-CH<sub>3</sub>; then

D is CH<sub>2</sub>, C=O, O, NH, N-CH<sub>3</sub>;

(4) that when n is 1, and

A is CH, C-SCH<sub>3</sub>, C-NH<sub>2</sub>, C-NHCH<sub>3</sub>, C-NHCOOCH<sub>3</sub>, C-NHCN, N; and  
B is CH, N; then

D is CH<sub>2</sub>, C=O, O, NH, N-CH<sub>3</sub>;

(5) that when n is 1, and

A is CH<sub>2</sub>, CHCH<sub>3</sub>, C=O, C=S, C=NH, SO<sub>2</sub>, and

B is CH, N; then

D is CH, N; [and] or pharmaceutically acceptable salts thereof to the human.

2 ~~8~~. (Previously amended) The method according to claim ~~7~~<sup>1</sup> where the compound of formula (A) is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione.

9. - 10. Previously cancelled

3 ~~11~~. (Original) The method according to claim ~~7~~<sup>1</sup> where the human is a male.

4 ~~12~~. (Previously amended) The method according to claim ~~7~~<sup>1</sup> where the human is a female.

13. Cancelled

14. Cancelled

15. Cancelled

16. Cancelled

5 ~~17~~. (Currently amended) The method according to claim [16] ~~7~~<sup>1</sup> where the sexually useful effective amount is from about 0.5 thru about 5 mg/person/dose.

6 ~~18~~. (Original) The method according to claim ~~7~~<sup>5</sup> where the sexually useful effective amount is from about 1 thru about 3 mg/person/dose.

19. - 20. Previously cancelled

7 21. (Previously amended) The method according to claim 7 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids: methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic,  $\text{CH}_3-(\text{CH}_2)_n-\text{COOH}$  where n is 0 thru 4, and  $\text{HOOC}-(\text{CH}_2)_n-\text{COOH}$  where n is as defined above.

8 22. (Original) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is administered from about 10 minutes to about 8 hr prior to sexual activity.

9 23. (Original) The method according to claim 22 where the compound of formula (A) pharmaceutically acceptable salt is administered from about 0.5 hr to about 1 hr prior to sexual activity.

10 24. (Original) The method according to claim 23 where the compound of formula (A) pharmaceutically acceptable salt is administered about 0.5 prior to sexual activity.

11 25. (Original) The method according to claim 7 where the human does not have Parkinson's disease.

12 26. (Original) The method according to claim 7 where the human does not experience postural hypotension.

13 27. (Original) The method according to claim 7 where the compound of formula (A) or pharmaceutically acceptable salt is used in combination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where the compound of formula (A) or pharmaceutically acceptable salt is administered within 8 hours prior to sexual activity and where the vascular smooth muscle relaxation agent is administered to the human within a sexually effective time period prior to sexual activity.

14 ~~28~~ <sup>13</sup> (Previously amended) The method according to claim ~~27~~ where the vascular smooth muscle relaxation agent is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin E1 receptor agonists, and vasoactive intestinal polypeptide agents.

15 ~~29~~ <sup>14</sup> (Previously amended) The method according to claim ~~28~~ where the vascular smooth muscle relaxation agent is selected from the group consisting of sildenafil, tadalafil, milrinone, papaverine, linsidomine, phentolamine, yohimbine, prostaglandin E1 receptor agonists, and vasoactive intestinal polypeptide agents.

16 ~~30~~ <sup>2</sup> (Previously amended) The method according to claim ~~8~~ where the pharmaceutically acceptable salt of the compound is (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione maleate.